Home  /  Resource Library  /  Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia

Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia

Results of a study examining ofatumumab and fresh frozen plasma for treatment of relapsed CLL.